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aorta, the most logical explanation may be related to the
rather short half-life (<10 seconds) of adenosine in blood
because of the very effective uptake by the red cells.11
The second article on which we would like to comment, by
Ross and associates, is titled “Hypothermic Retrograde
Venous Perfusion With Adenosine Cools the Spinal Cord and
Reduces the Risk of Paraplegia After Thoracic Aortic
Clamping” (J Thorac Cardiovasc Surg 2000;119:588-95).
1. Although apparently no statistically significant differ-
ence was reported between the adenosine group (III: Tarlov
score 4.7 ± 0.2) and the plain saline solution group (II: Tarlov
score 3.8 ± 0.4), no explanation is offered regarding the neu-
rologic recovery in group III, which seems to us significantly
better (P < .002).
2. Somatosensory evoked potentials (SSEPs) ceased signif-
icantly faster in the groups receiving regional infusion of
hypothermic solution (II and III) than in the normothermic
ischemia group (I), corroborating in the spinal cord a widely
known observation in the nonischemic brain (the electroen-
cephalogram becomes a straight line below 24°C-25°C) that
hypothermia markedly decreases all neural activity, transmis-
sion included. However, no differences were observed
between groups II and III (P = .86 according to our analysis
of the presented data). The authors’ conclusion that electrical
silence is the major determinant of protection seems not to be
substantiated by the significantly different neurologic out-
comes in two groups, in which SSEPs ceased within compa-
rable times after hypothermic perfusion.
3. The lesser amplitude of the postreperfusion returned
SSEP of group III (85% vs 90% of group II; whether differ-
ences would be statistically significant could not be calculat-
ed since no SDs are provided) was not unexpected, and the
better neurologic outcome can be explained by the same com-
ments (inhibitory effects of adenosine/taurine) made for the
previous article.
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Should methylene blue be the drug of choice to treat
vasoplegias caused by cardiopulmonary bypass and
anaphylactic shock?
To the Editor:
Yiu, Robin, and Pattison1 presented a rapid reversal of
refractory hypotension with methylene blue after cardiopul-
monary bypass (CPB). I would like to reinforce this kind of
therapeutic approach, not only for low systemic vascular
resistance (SVR) after CPB, but also for other types of vaso-
plegias, including anaphylactic shock.
My colleagues and I2 reported the restoration of SVR with
the use of methylene blue in 6 patients after cardiac surgery
with and without CPB. In the immediate postoperative peri-
od, all patients had tachycardia, oliguria, good peripheral per-
fusion, and important systemic arterial hypotension not
responsive to large doses of infused catecholamines.
Hemodynamic analysis, done by the thermodilution tech-
nique (Swan-Ganz; Baxter Healthcare Corp, Santa Ana,
Calif), showed a profile compatible with systemic inflamma-
tory response syndrome, with a mean SVR index of 868 dina
· s · cm5. Methylene blue was administered to block the action
of nitric oxide inhibiting the soluble guanylate cyclase at
doses of 1.5 mg/kg during 1 hour of intravenous infusion.
The systemic vascular tone restoration (SVR index = 1693
dina · s · cm5 with normal arterial pressure and clinical per-
formance) was effective and fast, showing methylene blue as
a pharmacologic tool that improves the morbidity and mor-
tality in systemic inflammatory response syndrome.
Methylene blue did not affect cardiac output or pulmonary
vascular resistance in those patients. This clinical experience
was started in 1994 with the use of methylene blue in des-
perate situations in the operating room and early hours of the
postoperative period. Since the presentation of these hemo-
dynamic data, methylene blue has been widely used in
Brazil.2 Trying to find cause-effect clues, we identified some
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isolated data3: (1) Most of the events were observed during or
after CPB. (2) Many cases were associated with the use of the
curare alcuronium. (3) Some cases were observed under
usual anesthesia with etomidate, fentanyl, pancuronium, and
diazepam. (4) Some cases were clearly associated with prot-
amine infusion. (5) At least in one case the vasodilatation was
induced after heparin infusion. (6) The vasoplegia was also
observed in noncardiac operations. (7) Our impression was
that the syndrome happened periodically. (8) Many patients
had diabetes. (9) Many patients were previously using the
calcium antagonist diltiazem. To these observations we can
add the possible effects of the angiotensin-converting enzyme
inhibitors as suggested by Tuman and associates4 and men-
tioned by Yiu, Robin, and Pattison.1
We also have used methylene blue to treat anaphylaxis.
Our cumulative clinical experience includes 6 patients. The
causes were iodinate radiographic contrast material (5
patients) and penicillin (1 patient). The traditional treatments
(high doses of epinephrine and corticosteroids) failed to
reverse the cardiocirculatory collapse, urticaria, and
angioedema. Four patients were treated by a bolus infusion
of 4% methylene blue, 1.5 mg/kg (120 mg), followed by
continuous infusion of another 120 mg diluted in 5% glucose
in water. The infusion was administered as a bolus because
of the severity of shock. Two patients received only continu-
ous infusion during 30 to 40 minutes. The anaphylactic man-
ifestations were completely reversed in 10 to 15 minutes. In
1 patient we observed nodal cardiac rhythm over 1 minute
during the infusion of the dye, which reversed spontaneous-
ly. One hypertensive patient had angina pectoris during infu-
sion, without any electrocardiographic manifestation, and
did not require coronary vasodilators to reverse the symp-
toms. We obtained the hemodynamic registers of 2 patients
who had anaphylactic shock caused by radiographic contrast
material in the cardiovascular catheterization laboratory.
Cumulative experience would indicate that this dye is the
treatment of choice or an alternative to the treatment of dis-
tributive circulatory shock. I am reporting, probably, the first
experience treating anaphylaxis in human beings with meth-
ylene blue, and it deserves wide circulation because it is a
lifesaving choice.5
Nitric oxide stimulates soluble guanylate cyclase and acti-
vates the production of cyclic guanosine 3´,5´monophos-
phate (cGMP), resulting in relaxation. Inhibition of nitric
oxide synthesis is not approved for clinical use because of
the lack of specificity to the inducible form of nitric oxide
synthase and its association with tissue necrosis. Methylene
blue inhibits guanylate cyclase, avoiding the cGMP-depen-
dent vasorelaxant effect of nitric oxide in the smooth muscle
of the vessels. Also, thiazine dye is widely used in clinical
medicine to reduce methemoglobin, to treat malaria, and to
cleanse the urinary tract. Otherwise, methylene blue is not
associated with tissue necrosis, as caused by nitric oxide
synthase inhibition, and its lethal dose is more than 40
mg/kg, as shown experimentally in sheep. Myles, Leong,
and Curry6 failed to identify an increase in nitric oxide
release after, or as a consequence of, CPB on the basis of the
serum and urine nitrite/nitrate levels. Since methylene blue
blocks the soluble guanylate cyclase, which is the final effect
on the nitric oxide pathway, it is hard to determine a differ-
ent cGMP-dependent mechanism, and the hypothesis of
direct activation of this final common pathway of nitric
oxide release is very improbable. I guess it is more logical to
speculate on the existence of another non-nitric cGMP-
dependent pathway, with different receptors and/or different
G-proteins, or else a sensitization of vascular smooth muscle
cells to the action of nitric oxide, as hypothesized by Yiu,
Robin, and Pattison.1
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Reply to the Editor:
We thank Evora for adding his experience with methylene
blue. In most instances of low systemic vascular resistance
(SVR) syndrome necessitating pharmacologic intervention,
vasopressor therapy over a number of hours is limited. Thus
whether methylene blue should be the drug of choice is
speculative at this stage. Nevertheless, in cases in which
first-line therapy has failed, the dramatic success and long-
lasting effect of this drug that we found in our case, and that
Evora and his colleagues presumably found as well, are cer-
tainly impressive. This leads us to propose that early use of
methylene blue may halt the progression of low SVR even
in patients responsive to norepinephrine and mitigate the
need for a protracted course of vasoconstrictor use. A ran-
The Journal of Thoracic and
Cardiovascular Surgery
Volume 119, Number 3
Letters to the Editor 633
